Compare Neurocrine Biosciences Inc (NBIX) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Standard Lithium Ltd — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Standard Lithium Ltd trades at $2.37 (market cap $589.88M). The key difference: Neurocrine Biosciences Inc is far larger — about 26.7× Standard Lithium Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| NBIX | SLI | |
|---|---|---|
Market Cap | $15.77B | $589.88M |
Sector | Health | Basic Materials |
52-Week High | $185.50 | $5.65 |
52-Week Low | $123.10 | $1.93 |
Enterprise Value | $15.78B | $452.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Standard Lithium (SLI) trades at $2.40, down 0.83% today, with a bullish technical signal despite negative profitability metrics. The company shows progress with recent DOE clearance and key customer agreements, including LG Energy Solution, while maintaining 100% analyst buy ratings. Cash flow remains positive primarily from financing activities, though operational cash flow is negative as the company invests heavily in lithium project development.
The outlook hinges on successful project execution and Final Investment Decision for the Arkansas lithium project, which could unlock $250 million in government funding. Key risks include execution delays and negative profitability, but strong institutional interest and supportive government policies for critical minerals provide upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
